Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Clinical Lung Cancer|June 14, 2023
Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101)Tetsuhiko Asao, Takehito Shukuya, Tomoyasu Mimori, et al.
JTO Clinical and Research Reports|August 9, 2022
The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLCHiroaki Kanemura, Hidetoshi Hayashi, Shuta Tomida, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2026
Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancerRoss A Soo, Pablo Fernandez-Penas, Molly Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2021
A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)Hidetoshi Hayashi, Shunichi Sugawara, Yasushi Fukuda, et al.
JTO Clinical and Research Reports|February 11, 2022
A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLCDaichi Fujimoto, Satoru Miura, Kenichi Yoshimura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2021
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung CancerKimio Yonesaka, Junko Tanizaki, Osamu Maenishi, et al.
Japanese Journal of Clinical Oncology|January 25, 2024
First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING studyHisao Imai, Takashi Kijima, Koichi Azuma, et al.
Scientific Reports|November 13, 2023
Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancerTakeshi Masuda, Satoru Miura, Yuki Sato, et al.
Oncology Letters|August 7, 2023
Novel single nucleotide polymorphism biomarkers to predict opioid effects for cancer painYoshihiko Fujita, Hiromichi Matsuoka, Yasutaka Chiba, et al.
Cells|March 26, 2025
Chromosomal Instability Is Associated with cGAS-STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung CancerKimio Yonesaka, Takashi Kurosaki, Junko Tanizaki, et al.
Pageof 7